摘要
Background The current risk stratification system defined by clinicopathological features does not identify the risk of recurrence in early-stage (stage I-II) colorectal cancer (CRC) with sufficient accuracy. We aimed to investigate whether DNA methylation could serve as a novel biomarker for predicting prognosis in early-stage CRC patients. Methods We analyzed the genome-wide methylation status of CpG loci using Infinium MethylationEPIC array run on primary tumor tissues and normal mucosa of early-stage CRC patients to identify potential methylation markers for prognosis. The machine-learning approach was applied to construct a DNA methylation-based prognostic classifier for early-stage CRC (MePEC) using the 4 gene methylation markers FAT3, KAZN, TLE4, and DUSP3. The prognostic value of the classifier was evaluated in 2 independent cohorts (n = 438 and 359, respectively). Results The comprehensive analysis identified an epigenetic subtype with high risk of recurrence based on a group of CpG loci in the CpG-depleted region. In multivariable analysis, the MePEC classifier was independently and statistically significantly associated with time to recurrence in validation cohort 1 (hazard ratio = 2.35, 95% confidence interval = 1.47 to 3.76, P < .001) and cohort 2 (hazard ratio = 3.20, 95% confidence interval = 1.92 to 5.33, P < .001). All results were further confirmed after each cohort was stratified by clinicopathological variables and molecular subtypes. Conclusions We demonstrated the prognostic statistical significance of a DNA methylation profile in the CpG-depleted region, which may serve as a valuable source for tumor biomarkers. MePEC could identify an epigenetic subtype with high risk of recurrence and improve the prognostic accuracy of current clinical variables in early-stage CRC.
学科与关键词
- Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markersYang, Xin; Wen, Xiaofeng; Guo, Qin; Zhang, Yunfeng; Liang, Zhenxing; Wu, Qian; Li, Zhihao; Ruan, Weimei; Ye, Zhujia; Wang, Hong; Chen, Zhiwei; Fan, Jian-Bing; Lan, Ping*; Liu, Huashan*; Wu, Xianrui*Clinical Epigenetics, 2022, 14(1): 160.被引 3
- Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cell-free DNAWang, Wei; Zhu, Xiaohui; Zhang, Xuecong; Lei, Chengyong; Zeng, Zhicheng; Lan, Xiaoliang; Cui, Wenzhi; Wang, Feifei; Xu, Shaowan; Zhou, Juan; Wu, Xuehui; Deng, Haijun; Li, Xia; Fan, Jianbing*; Ding, Yanqing*; Huang, Zhongxi*; Liang, Li*Journal of Pathology, 2023, 259(4): 376-387.被引 1
- Identification of DNA methylation biomarkers for risk of liver metastasis in early-stage colorectal cancerLi, Weihua; Guo, Lei; Tang, Wanxiangfu; Ma, Yutong; Wang, Xiaonan; Shao, Yang; Zhao, Hong*; Ying, Jianming*CLINICAL EPIGENETICS, 2021, 13(1): 126.
